Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 1
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Mucopolysaccharidosis Type II (Hunter Syndrome): clinical picture and treatment.
Beck M. Beck M. Curr Pharm Biotechnol. 2011 Jun;12(6):861-6. doi: 10.2174/138920111795542714. Curr Pharm Biotechnol. 2011. PMID: 21235446 Review.
Mucopolysaccharidosis (MPS) type II (Hunter syndrome, OMIM 309900) is an X-linked lysosomal storage disorder caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (IDS). ...Until recently, no specific treatment was available for the affected patients; …
Mucopolysaccharidosis (MPS) type II (Hunter syndrome, OMIM 309900) is an X-linked lysosomal storage disorder caused by a defic …
Management of the behavioural manifestations of Hunter syndrome.
Roberts J, Stewart C, Kearney S. Roberts J, et al. Br J Nurs. 2016 Jan 14-27;25(1):22, 24, 26-30. doi: 10.12968/bjon.2016.25.1.22. Br J Nurs. 2016. PMID: 26768041 Review.
This article reviews the behavioural manifestations of, and the strategies for managing, Hunter syndrome (mucopolysaccharidosis (MPS) type II), a rare X-linked lysosomal storage disorder caused by a deficiency of the enzyme iduronate-2-sulphatase. Hunter syndrome is …
This article reviews the behavioural manifestations of, and the strategies for managing, Hunter syndrome (mucopolysaccharidosis (MPS) …
Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders.
Miebach E. Miebach E. Int J Clin Pharmacol Ther. 2009;47 Suppl 1:S100-6. doi: 10.5414/cpp47100. Int J Clin Pharmacol Ther. 2009. PMID: 20040319
OBJECTIVE: Enzyme replacement therapy (ERT) is currently available for the treatment of mucopolysaccharidosis (MPS) Type I, MPS II and MPS VI. ...When ERT was restarted, patients were given premedication in the form of antihistamines and antipyretics, …
OBJECTIVE: Enzyme replacement therapy (ERT) is currently available for the treatment of mucopolysaccharidosis (MPS) Type I, MP …